Rybelsus is the brand name for the oral tablet formulation of semaglutide used to treat type 2 diabetes in adults
GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation
Quick Answer: GLP-1 receptor agonists increase heart rate by an average of 14 beats per minute through mechanisms including sympathetic nervous system activation, hemodynamic changes, and potential effects on cardiovascular regulation pathways
Diabetes Care Center, Jinnouchi Hospital, 6-2-3 Kuhonji, Chuo-ku, Kumamoto 862-0976, Japan Tel: +81-96-363-0011, Fax: +81-96-364-2654, E-mail: [email protected] Copyright 2025 Korean Endocrine Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
Semaglutide is the active ingredient in the following brand-name drugs: Ozempic, Wegovy, and Rybelsus